The world-renowned GPCR specialist will assemble a team of experts in drug discovery and development to guide Domain’s programs,/i>
Strasbourg, France, September 22, 2014 – Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new medicines targeting G protein-coupled receptors (GPCRs), today announces the nomination of Michel Bouvier as chairman of the company’s Scientific Advisory Board.
Michel Bouvier, PhD, is a professor in the Department of Biochemistry and Molecular Medicine at the University of Montreal and also chief executive officer of the Institute for Research in Immunology and Cancer (IRIC). In the coming months, he will work closely with Domain Therapeutics’ management team to assemble a group of academic and industrial peers.
“We are honored that an internationally renowned key opinion leader in GPCRs will advise on the technology and scientific evolution at our company”, said Pascal Neuville, board director and CEO of Domain Therapeutics. “His seminal contributions to our understanding of this major class of drug targets are invaluable and have led to paradigm shifts and the development of new classes of drugs. His remarkable skills in bridging basic research, drug discovery and medical needs will help Domain to reach its future goals and to maintain its leadership in the GPCR area.”
Michel Bouvier contributed to establishing the concept of ligand-biased signalling. He pioneered the use of bioluminescence resonance energy transfer (BRET)-based methods for the study of functional selectivity of GPCRs. These concepts are now integrated in Domain Therapeutics’ platform, BioSens-All(TM).
Professor Bouvier conducted post-doctoral training at Duke University under the direction of Robert Lefkowitz, winner of the 2012 Nobel Prize for Chemistry for his contribution in the GPCR field. Professor Bouvier was awarded the Hans-Selye/Bristol-Myers Squibb chair in Cell and Molecular Biology and the Merck-Frosst award from the Canadian Society of Biochemistry and Molecular & Cell Biology. He now holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology. Professor Bouvier is a fellow of the Canadian Academy of Health Sciences and of the Royal Society of Canada.
“I look forward to helping guide the development of Domain Therapeutics’ research and development programs in the GPCR field”, said Professor Michel Bouvier. “The potential of the technologies assembled by Domain and the achievements made to date are great and constitute the groundwork for the company’s future success.”
About Domain Therapeutics
Domain Therapeutics is a biopharmaceutical company based in Strasbourg, France. It is dedicated to the discovery and early development of small molecules targeting G protein-coupled receptors (GPCRs), one of the most important classes of drug targets. Domain identifies and develops new drug candidates, allosteric modulators and biased ligands through its innovative approach and distinctive technologies.
The company provides access to its technologies through research and collaborative agreements and develops its own pipeline for components up to the stage of optimized lead product for major indications in central nervous system and metabolic disorders. In January 2014, the company established its subsidiary, Domain Therapeutics NA Inc., at the NEOMED Institute in Montreal, Canada.
Find out more - http://www.domaintherapeutics.com
To read the original release - http://www.ala.com/article.php?id=456
Mark Tidmarsh
mark@ala.com
ANDREW LLOYD & ASSOCIATES
http://www.ala.com
https://twitter.com/ALA_Group
Tel UK: +44 1273 675100
Tel France: +33 1 56 54 07 00
Tel US: +1 617 517 0146
